Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re:BARCO’S MOTION FOR SUMMARY JUDGMENT OF NONINFRINGEMENT ...Mark

Mark you have had Quanta on the brain ever since you connected the dots in your own mind. Your assumptions do not make a fact.

These are the press releases issued by TPL/PTSC. Note the confidentiality statements.

EOT

2007-12-18 B

TPL, Toshiba, Matsushita (Panasonic), and JVC Resolve Their Dispute Over the Moore Microprocessor Patent Portfolio

CUPERTINO, Calif.--(BUSINESS WIRE)--The TPL Group, Patriot Scientific Corporation, Toshiba, Matsushita (Panasonic) and JVC announced today that they have entered into a business resolution of their legal disputes in two patent infringement lawsuits pending in the US District Courts in the Eastern District of Texas and the Northern District of California. The terms of their settlement include the grant by the TPL Group of rights under the Moore Microprocessor Patent Portfolio to Toshiba, Matsushita and JVC and their respective subsidiaries. The parties have agreed that the details of the settlement are confidential. All parties are pleased with the business resolution of their dispute and will be voluntarily dismissing their Texas and California lawsuits.

2007-12-18 C

Note Regarding Settlement from CEO Jim Turley

Shareholders are advised that the following is the only information that will be provided by Patriot Scientific Corporation regarding the resolution of the Texas (and California) litigation that had been pending regarding the MMP portfolio patents subject to the dispute:

Patriot Scientific Corporation, its directors, officers and employees are obligated to observe the confidentiality provisions of the settlements and will limit any comments or statements solely to references to the wording of the joint press release or statements that matters between the parties to the litigation have been settled.

This settlement occurred during Patriot's current financial quarter, which ends February 28, 2008, and for which financial reports will be due for filing with the SEC by the second week of April, 2008. Information applicable to this settlement will be included in those reports to the extent required of the company, yet consistent with the confidentiality restrictions imposed by the settlement pursuant to guidance from Patriot's professional legal and accounting advisors.

In addition, consistent with applicable securities laws and Patriot's insider-trading policy, the company's directors, officers, employees and consultants who have knowledge of the terms of settlement are restricted from trading in PTSC shares until after the company's quarterly financial reports are publicly filed next April.

We realize that our shareholders may expect that the details of the settlement should be made available to them, or that Patriot's board and management might provide at least general comments or further press releases on the subject. We understand this and would do so if permitted, but in order to honor our legal commitments regarding confidentiality, we have said all we can say.

—Jim Turley

2008-04-10

Letter to Shareholders from Patriot Scientific President and CEO Rick Goerner

Requests for details regarding specific MMP™ portfolio licenses

Patriot cannot, and will not, disclose the details of individual license agreements on the MMP™ portfolio.
I understand that this remains a clear source of frustration with our shareholders.

Share
New Message
Please login to post a reply